The US FDA is to fund a new study at the University of Cincinnati (UC) aimed at ending questions over generic versus brand, and generic versus generic, for tacrolimus – an immunosuppressive drug for transplant patients.
The FDA put out the 'RFA' call back in April for interested parties to apply for the funding opportunity. The...
Welcome to Scrip
Create an account to read this article
Already a subscriber?